Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on June 22, 2021, covering events that occurred on January 22, 2021, and June 1, 2021. The Company is an emerging growth company incorporated in Nevada, with its principal executive offices in La Jolla, California. The filing primarily addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements under the Company's 2021 Stock Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation grants and does not contain financial statement data.
Material Changes and Equity Grants
The Company reported the following material changes regarding equity compensation approved by the Compensation Committee on January 22, 2021, under the 2021 Stock Incentive Plan (approved by stockholders on June 1, 2021):
- Non-Employee Directors: Options to purchase an aggregate of 95,125 shares were granted (19,025 shares per director). These options have an exercise price of $17.49 per share and vest quarterly over three years.
- Chief Executive Officer (Ramond J. Tesi): An option to purchase 70,663 shares was granted with an exercise price of $17.49 per share.
- Chief Financial Officer (David Moss): An option to purchase 70,663 shares was granted with an exercise price of $17.49 per share.
- Executive Vesting Schedule: For the CEO and CFO, 25% of the options vest 12 months from the grant date, with the remainder vesting pro rata monthly over the subsequent three years (1/36 per month), reaching 100% vesting on the four-year anniversary of the grant date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is limited to the disclosure of specific stock option agreements.
Investor Verification Checklist
- Verify the total number of shares available under the 2021 Stock Incentive Plan (2,000,000 shares) and the impact of these new grants on the remaining pool.
- Confirm the exercise price of $17.49 per share relative to the current market price of INMB common stock.
- Review the specific terms of the option agreements filed as Exhibits 10.1 and 10.2 for any additional vesting conditions or acceleration clauses.
- Monitor future filings for the execution of the stock option agreements with the named officers and directors.